Investors in REGENXBIO, Inc. Should Prepare for Securities Fraud Action

Investors Take Note: Opportunity to Lead in REGENXBIO Securities Lawsuit

The Rosen Law Firm, renowned for its dedication to investor rights, has issued an important reminder for individuals who purchased securities of REGENXBIO, Inc. (NASDAQ: RGNX) during the critical period spanning from February 9, 2022, to January 27, 2026. This period marks the timeframe during which there are significant allegations of securities fraud against the company, and the firm is actively encouraging affected investors to come forward.

Class Action Participation and Lead Plaintiff Deadline

Those who have invested in REGENXBIO are urged to consider joining a class action lawsuit that has already been initiated. This class action offers a chance for investors to potentially receive compensation for their claims without upfront costs, thanks to a contingency fee arrangement. Importantly, the deadline to apply to be a lead plaintiff in this suit is April 14, 2026. A lead plaintiff represents the interests of all class members, directing the litigation process.

For individuals interested in seeking more information about this opportunity or participating in the class action, they can visit the Rosen Law Firm's dedicated page here, call Phillip Kim, Esq. at 866-767-3653, or send an email inquiry to [email protected].

Background of the Lawsuit and Alleged Misconduct

The heart of the allegations centers around claims made by REGENXBIO regarding its gene therapy candidate RGX-111, intended for treating severe Mucopolysaccharidosis Type I (commonly known as Hurler syndrome). The lawsuit claims that the defendants, who are associated with REGENXBIO, misled investors by communicating excessively optimistic expectations about RGX-111's success based on positive biomarkers and safety analyses from ongoing clinical trials.

However, these assertions were reportedly made alongside the suppression of negative information related to the efficacy and safety of the clinical trials. As a result, when the true nature of the situation became apparent, investors faced losses, leading to the current legal actions.

Rosen Law Firm emphasizes the importance of selecting the right legal representation when it comes to securities class actions. Many firms do not have the requisite experience in handling such lawsuits, which can disadvantage investors. The Rosen Law Firm has gained recognition for its commitment, managing to achieve one of the largest securities settlements against a Chinese company and being consistently recognized for their success in managing securities class actions.

Steps for Interested Investors

For those who believe they may have a claim as part of this class action against REGENXBIO, taking prompt action is critical. The firm has highlighted that while a class has not yet been certified, interested parties should be proactive in either finding representation or opting to remain as potential class members. It's advised for affected investors not to delay in making their decision because eligibility for future recovery might depend on their timely participation.

As updates regarding the progress of this lawsuit will be forthcoming, Rosen Law Firm encourages interested parties to stay connected via their social media channels, including LinkedIn, Twitter, and Facebook.

In summary, this serves as a pivotal moment for investors in REGENXBIO, Inc. In light of the actions being undertaken by the Rosen Law Firm and the serious accusations levied against the company, it is imperative for shareholders to consider their rights and the opportunity to obtain recompense for any possible losses incurred during the specified class period.